Increase and plateau orf CD4 T-cell counts in the 3-1/2 years after initiation of potent antiretroviral therapy

Article Abstract:

Highly active antiretroviral therapy (HAART) will decrease viral levels and increase CD4 T cell count, but only up to a certain point. About three years after treatment starts, both viral levels and CD4 T cell counts reach a plateau and don't change any further.

Physiological aspects, Anti-HIV agents

---

Effectiveness of Potent Antiretroviral Therapy on Time to AIDS and Death in Men With Known HIV Infection Duration

Article Abstract:

Potent antiretroviral drugs have significantly delayed the progression of HIV infection to AIDS, and improved the survival of HIV patients. Researchers compared 536 patients who contracted HIV from 1984 to 1997. Early HIV treatment was with a single drug, such as zidovudine, while patients infected later used combined drug therapy and, recently, potent antiretroviral drugs. Patients treated with antiretroviral drugs progressed to AIDS later than those given monotherapy or combined drug therapy, and patients on antiretroviral agents had slower declines in CD4 white blood cell counts.

Evaluation, Development and progression, Drug therapy, Antiviral agents, AIDS (Disease), Zidovudine

---

Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1-infected individuals

Article Abstract:

The authors explore the relationship between the use of antiretroviral therapy for HIV-infected patients and the incidence of either Kaposi's sarcoma (KS) or non-Hodgkin's lymphoma (NHL). They found that the incidence of KS had declined significantly but that cases of NHL continued to rise.

Health aspects, Statistical Data Included, Complications and side effects, Statistics, HIV patients, Non-Hodgkin's lymphomas, Kaposi's sarcoma, Antirheumatic agents

Similar abstracts:

• Abstracts: Impact of highly active antiretroviral therapy on anemia and relationship between anemia and survival in a large cohort of HIV-infected women: women's interagency HIV study.
• Abstracts: Impact of Folic Acid Fortification of the US Food Supply on the Occurrence of Neural Tube Defects. Food Fortification to Prevent Neural Tube Defects: Is It Working?
• Abstracts: Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: Results of AIDS clinical trials group 5108 study
• Abstracts: Survival after AIDS-defining events in patients with fewer than 200 lymphocytes CD4+ x 10(super)6/L who are toxoplasmosis antibody positive

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.